Alnylam Pharmaceuticals, Inc. (alny)
ALNY News
Live headlines and press releases for Alnylam Pharmaceuticals, Inc. load in the terminal.
Company news & press releases is available in Vest Terminal for Professional and Enterprise subscribers.
Start Free — open ALNY in Vest Terminal
Access live data, filings, ownership, and analysis for Alnylam Pharmaceuticals, Inc..
Alnylam Pharmaceuticals, Inc. FAQ
What does Alnylam Pharmaceuticals, Inc. (ALNY) do?
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUT…
What is ALNY's P/E ratio?
Alnylam Pharmaceuticals, Inc. has a trailing P/E of 43.86× based on publicly available market data.
Does ALNY pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is ALNY in?
Alnylam Pharmaceuticals, Inc. is classified in Healthcare (Biotechnology) on NMS.
What is ALNY's market capitalization?
Approximate market cap: $32.99B.
What are the main risks for ALNY?
Key risks include elevated valuation, among factors on this page.
What are the strengths of ALNY?
Potential positives include revenue growth of 66.9% year-over-year, return on equity near 96.6% — efficient use of shareholder capital.
Where can I get analyst estimates for ALNY?
Public analyst price targets and consensus for Alnylam Pharmaceuticals, Inc. are on the free /stocks/alny/estimates page. Deeper estimate history and models are available in Vest Terminal.